Preclinical Evaluation of a New Series of Albumin-Binding (177)Lu-Labeled PSMA-Based Low-Molecular-Weight Radiotherapeutics

Prostate-specific membrane antigen (PSMA)-based low-molecular-weight agents using beta(β)-particle-emitting radiopharmaceuticals is a new treatment paradigm for patients with metastatic castration-resistant prostate cancer. Although results have been encouraging, there is a need to improve the tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Boinapally, Srikanth, Alati, Suresh, Jiang, Zirui, Yan, Yu, Lisok, Alla, Singh, Rajan, Lofland, Gabriela, Minn, Il, Hobbs, Robert F., Pomper, Martin G., Banerjee, Sangeeta Ray
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10459686/
https://www.ncbi.nlm.nih.gov/pubmed/37630410
http://dx.doi.org/10.3390/molecules28166158

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10459686/
https://www.ncbi.nlm.nih.gov/pubmed/37630410
http://dx.doi.org/10.3390/molecules28166158

Ejemplares similares